Goldman Sachs
GENB icon

Goldman Sachs’s Generate Biomedicines GENB Stock Holding History

Goldman Sachs’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$189K Sell
11,183
-159,512
-93% -$2.17M ﹤0.01% 6211
2026
Q1 		$2.13M Buy
+170,695
New +$2.08M ﹤0.01% 4478

Other funds holding GENB

Flagship Pioneering
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Braidwell
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Arch Venture Management
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Harbourvest Partners
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Goldman Sachs's GENB Position: Q2 2026 in Review

Goldman Sachs reduced its Generate Biomedicines (GENB) stake by 93% in Q2 2026, selling an estimated $2.17M and leaving 11,183 shares worth $189K. The position accounts for ﹤0.01% of the portfolio, ranked #6211.

Goldman Sachs first reported a position in GENB in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.13M in Q1 2026. 86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • Goldman Sachs held 11,183 shares of Generate Biomedicines worth $189K as of Q2 2026.
  • Goldman Sachs sold 159,512 Generate Biomedicines shares in Q2 2026, an estimated $2.17M.
  • Generate Biomedicines made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6211 holding.
  • Goldman Sachs first reported a position in Generate Biomedicines in Q1 2026 and has held it in 2 quarters since.
  • Goldman Sachs's Generate Biomedicines position peaked at $2.13M in Q1 2026.
  • 86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.